熱門資訊> 正文
早些时候报道，Apellis获得FDA批准EMPAVELI治疗罕见肾病C3 G和IC-MPGN，蛋白尿减少68%
2025-07-29 15:32
- Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits
- Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence
- Well-established safety profile, consistent across >2,200 patient years in approved indications
- C3G and primary IC-MPGN are rare kidney diseases with high risk of kidney failure
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
